SCHEMBL17834612

SCHEMBL17834612

Cc1cc(C)cc(-c2ccc(-c3cnc(-c4ccc(C[C@H](NC(=O)c5ccc(C(C)(C)C)s5)C(=O)N5CC(C(=O)O)C5)cc4)nc3)c(F)c2)c1

nearest known ligand 0.34

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PRSS1 P07477 2/20 0.34
TMPRSS15 P98073 2/20 0.34
PYGL P06737 1/20 0.34
ITGB1 P05556 4/20 0.33
ITGA5 P08648 4/20 0.33
DPP4 P27487 1/20 0.33
KIFC1 Q9BW19 2/20 0.33
ALOX5AP P20292 4/20 0.33
FEN1 P39748 4/20 0.33
ITGB3 P05106 3/20 0.32
ITGAV P06756 3/20 0.32
ITGA2B P08514 3/20 0.32
ITGB5 P18084 3/20 0.32
S1PR1 P21453 2/20 0.32
S1PR3 Q99500 1/20 0.32
SYK P43405 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17834881 0.95 S1PR1 (0.35) PRSS1TMPRSS15PYGLITGB1ITGA5
SCHEMBL17834419 0.95 S1PR1 (0.35) PRSS1TMPRSS15PYGLITGB1ITGA5
SCHEMBL17834597 0.94 FEN1 (0.34) PRSS1TMPRSS15PYGLITGB1ITGA5
SCHEMBL17995211 0.93 DPP4 (0.37) PRSS1TMPRSS15PYGLITGB1DPP4
SCHEMBL17834870 0.93 PYGL (0.38) PYGLITGB1ITGA5DPP4S1PR1
SCHEMBL19485597 0.92 ALOX5AP (0.35) PRSS1TMPRSS15PYGLITGB1DPP4
SCHEMBL17834639 0.92 S1PR1 (0.38) PRSS1TMPRSS15PYGLDPP4KIFC1
SCHEMBL17834633 0.92 F2 (0.35) PRSS1TMPRSS15PYGLDPP4KIFC1
SCHEMBL19807140 0.92 FEN1 (0.34) PRSS1TMPRSS15PYGLITGB1DPP4
SCHEMBL19485649 0.92 KIFC1 (0.35) PYGLITGB1ITGA5DPP4KIFC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3230276-B1 GLP-1 RECEPTOR MODULATORS CELGENE INT II SARL (CH) 2020-09-02 EP disclosed
US-10034886-B2 GLP-1 receptor modulators CELGENE INTERNATIONAL II SÀRL (CH) 2018-07-31 US disclosed
US-20180021346-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2018-01-25 US disclosed
US-9795613-B2 GLP-1 receptor modulators CELGENE INTERNATIONAL II SÀRL (CH) 2017-10-24 US disclosed
US-20160228450-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2016-08-11 US disclosed
WO-2016094729-A1 GLP-1 RECEPTOR MODULATORS CELGENE INTERNATIONAL II SARL (CH) 2016-06-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160228450-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R PRSS1 1124/4885TMPRSS15 983/4885PYGL 779/4885
US-20180021346-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R PRSS1 1124/4885TMPRSS15 983/4885PYGL 779/4885
US-10034886-B2 GLP-1 receptor modulators GLP1R, GIPR, GCGR PRSS1 1261/4885TMPRSS15 1071/4885PYGL 607/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.